Contact
searchSearch
HMP Global
Login

Who May Benefit From a 2nd Generation TKI in First Line Management of Chronic Phase CML?

LL&M Great Debates 2020

Recent News

News
Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
09/15/2026
Emily Estrada
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3...
09/15/2026
Oncology
News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology
News
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
09/15/2026
Emily Estrada
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study...
09/15/2026
Oncology
News
Real-World Study Links Hyperlipidemia With Thrombosis in Essential Thrombocythemia
09/15/2026
Stephanie Holland
Real-world findings suggest that cardiovascular comorbidities, particularly hyperlipidemia and potentially hypertension, may contribute to thrombotic risk in essential thrombocythemia beyond conventional disease-related factors, supporting...
Real-world findings suggest that cardiovascular comorbidities, particularly hyperlipidemia and potentially hypertension, may contribute to thrombotic risk in essential thrombocythemia beyond conventional disease-related factors, supporting...
Real-world findings suggest that...
09/15/2026
Oncology
News
Mutant CALR-Targeted INCA033989 Shows Promising Activity in Treatment-Resistant Essential Thrombocythemia
09/15/2026
Stephanie Holland
INCA033989 demonstrated rapid and durable hematologic responses with molecular evidence of reduced mutant CALR burden in patients with CALR-mutant essential thrombocythemia resistant or intolerant to cytoreductive therapy, supporting further...
INCA033989 demonstrated rapid and durable hematologic responses with molecular evidence of reduced mutant CALR burden in patients with CALR-mutant essential thrombocythemia resistant or intolerant to cytoreductive therapy, supporting further...
INCA033989 demonstrated rapid...
09/15/2026
Oncology
FDA Approval
BEXLUTRY Becomes First FDA-Approved Radioligand Equivalent for Adults With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors
09/15/2026
Stephanie Holland
The FDA has approved BEXLUTRY, a lutetium Lu 177 dotatate radioligand therapy, for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, introducing the first radioligand equivalent to LUTATHERA and...
The FDA has approved BEXLUTRY, a lutetium Lu 177 dotatate radioligand therapy, for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, introducing the first radioligand equivalent to LUTATHERA and...
The FDA has approved BEXLUTRY, a...
09/15/2026
Oncology
News
MRI-Adapted M-RECIST Better Characterizes Treatment Response After Cryoablation in Desmoid-Type Fibromatosis
09/14/2026
Emily Estrada
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified...
09/14/2026
Oncology
News
Novel NLRP3 Inhibitor Ofirnoflast Demonstrates Clinical Activity in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial...
09/14/2026
Oncology
News
Luspatercept Provides Durable Transfusion Independence in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the...
09/14/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use